Investor Presentation

Date: 19th August, 2026 To, To, The Manager (Listing) Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No. C/1, G Block, Dalal Street, Fort, Bandra-Kurla Complex, Mumbai - 400001 Bandra (E), Mumbai – 400051 BSE Scrip Code: 506260 NSE Symbol: ANUHPHR; Series: EQ Sub: Investor Presentation – Q1 FY 2026-27. Dear Sir/Madam, With reference to the subject mentioned above and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith Investor Presentation for Q1 FY 2026-27. This intimation is also being uploaded on the Company's website at www.anuhpharma.com. Kindly take the above on your records. Thanking you, Yours faithfully, FOR ANUH PHARMA LIMITED MANAN VADHAN COMPANY SECRETARY & COMPLIANCE OFFICER Encl: As above ANUH PHARMA LTD. Investor Presentation Q1 FY27 | August 2026 BSE - 506260, NSE- ANUHPHR Bloomberg: ANUH IN | Reuters: ANUH.BO www.anuhpharma.com Safe Harbour Statement ▪ This presentation may include certain "forward looking statements", based on current expectations, within the meaning of applicable laws and regulations. ▪ Actual results may differ and the Company does not guarantee realization of these statements. The Company also disclaims any obligation to revise any forward-looking statements. ▪ The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein. ▪ No part of this presentation may be reproduced, quoted or circulated without prior written approval from Anuh Pharma Limited. Anuh Pharma Limited | Investor Presentation Q1 FY27 Q1 FY27 & FY26 Performance Company Overview Table of Contents Infrastructure Future Outlook Corporate Social Responsibility Q1 FY27 & FY26 Performance Q1 FY27 at a Glance Rs. in Crores Operating Revenue Operating Profit EBITDA Profit Before Tax 193.81 38.15 19.36 16.93 +3.93% YoY +39.50% YoY +41.56% YoY +54.55% YoY Rs. 186.48 Cr in Q1 FY26 19.68% margin 9.99% margin vs 7.34% LY 8.74% margin vs 5.87% LY PAT ROCE EPS (Rs.) Production (MT) 11.42 19.18% 1.14 491 MT +37.63% YoY +326 bps vs FY26 +37.63% YoY +19.46% YoY 5.89% margin vs 4.45% LY FY26: 15.92% Q1 FY26: Rs. 0.83 Q1 FY26: 411 MT Message from the Joint Managing Directors – Q1 FY27 Q1 FY27 – PROFITABILITY Dear Shareholders, Investors and Partners, 193.81 Revenue (Cr) +3.93% FY27 has opened on a confident note, with profit growth running well ahead of revenue - a deliberate outcome of our shift towards higher-value products in regulated markets. 19.36 EBITDA (Cr) +41.56% Three levers drove the quarter: a richer product mix, disciplined cost control, and better throughput from existing assets - 11.42 PAT (Cr) +37.63% together lifting margins at every level of the P&L. With USFDA and EU GMP clearances secured, the regulated- market pipeline is now our primary engine of growth, with Q1 FY27 – OPERATIONS & RETURNS returns strengthening without added leverage. We thank you for your trust and reaffirm our commitment to Production (MT) +19.46% sustainable, profitable growth. 16.93 PBT (Cr) +54.55% Ritesh Shah, Joint MD | Vivek Shah, Joint MD 19.18% ROCE +326 bps Q1 FY27 Financial Performance Rs. in Crores Financial Highlights Q1 FY27 Q4 FY26 % QoQ Q1 FY26 % YoY Operating Revenue 193.81 202.12 (4.11) 186.48 3.93 Operating Profit * 38.15 44.44 (14.15) 27.35 39.50 % of Margin 19.68 21.99 14.66 Other Income 3.08 (1.25) (345.23) 3.39 (9.20) EBITDA 19.36 18.63 3.95 13.68 41.56 % of Margin 9.99 9.22 7.34 Interest 0.00 0.11 (96.73) 0.21 (98.36) Depreciation 2.43 3.00 (18.98) 2.52 (3.27) PBT 16.93 15.52 9.08 10.95 54.55 TAX 5.50 3.84 43.38 2.65 107.52 PAT 11.42 11.68 (2.20) 8.30 37.63 Reported EPS (Rs.) 1.14 1.17 (2.20) 0.83 37.63 * Operating Profit = PBT + Depreciation + Other Expenses - Other Income. Figures in brackets denote decline. Five-Year Financial Track Record Rs. in Crores | FY22 - FY26 Total Revenue EBITDA 87.2 776.0 70.4 659.0 671.0 66.1 57.4 491.8 537.0 52.0 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Profit Before Tax and Profit After Tax PBT PAT 78.3 60.1 61.0 54.2 47.5 47.4 47.4 39.1 36.2 30.6 FY22 FY23 FY24 FY25 FY26 Balance Sheet Strength & Shareholder Returns FY22 - FY26 Dividend Outflow (Rs. Cr.) Current Ratio (x) 2.22 2.20 15.03 15.03 2.11 12.53 10.02 8.77 1.98 1.91 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Debt to Equity (x) Cash Conversion Cycle (Days) 0.03 86 58 56 61 0.01 0.01 0.00 0.00 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 # FY26 dividend as proposed. Revenue Mix & Customer Concentration Q1 FY27 vs Q1 FY26 Domestic vs Export Revenue (Rs. Cr.) Top 5 Customers - Share of Sales Domestic Export Q1 FY27 Q1 FY26 37% 36% Q1 FY27 Q1 FY26 Export Domestic Total Export Revenue by Geography % of export sales Q1 FY27 Q1 FY26 2.6% 3.1% 26.8% 27.9% 35.7% 30.9% 4.2% 3.8% 35.5% 29.6% Asia Europe North America Asia Europe North America Africa Latin America Africa Latin America Product Mix - Q1 FY27 vs Q1 FY26 Rs. in Crores Revenue by Product Group Q1 FY27 Q1 FY26 49.1 Erythromycin 63.6 39.9 Higher Macrolides 19.7 37.0 Sulphadoxine 11.0 20.1 Cortico Steroids 20.9 12.2 Pyrazinamide 10.3 11.9 Gliclazide 10.9 Other Items 34.7 Ambroxol HCL Chloramphenicol 12.2 Company Overview Anuh Pharma at a Glance API manufacturer since 1989 ~46% 360 72+ 2 of FY26 revenue from marketing partners / countries served facilities - Tarapur & exports customers Mahape Business Profile Infrastructure & Group ▪ One of the largest manufacturers of Macrolides and ▪ Manufacturing facility at Tarapur over 11,400 sq. mtrs of Anti-TB products in India. land, including a newly acquired plot of 7,800 sq. mtrs. ▪ Major player in Anti-bacterials, Anti-malarial, Anti- ▪ R&D facility at Mahape spread over 10,000 sq. ft. hypertension and Corticosteroids. ▪ Expansion project targeted at regulated markets ▪ Strong marketing partnerships with 360 customers in completed; commercial production started w.e.f. 21st over 72 countries, including Europe, Mexico and South December 2019. Africa. ▪ Part of the INR 8.5 bn SK Group, employing ~2,200 ▪ The Company derived ~46% of its revenues from people across pharma formulations, trading, distribution exports in FY26. and logistics. Journey So Far 1989 - 2026 FOUNDATION 1989 - 2010 GLOBAL APPROVALS 2012 - 2019 SCALE & GROWTH 2020 - 2026 1989 Started manufacturing 2012 Acquired R&D assets of Invent 2020 WHO Geneva pre-qualification Erythromycin salts with capacity of 150 Pharma (Spain); DSIR approval. for Pyrimethamine API. MTPA. 2014 COFEPRIS Mexico approval for 2023 CEP from EDQM for 1995 Doubled the capacity to 300 three Erythromycin salts. Sulphadoxine, Azithromycin & MTPA. Gliclazide; capacity to 1,800 MTPA. 2015 COFEPRIS Mexico for 2002 Received WHO-GMP for its Chloramphenicol & Palmitate; WHO 2024 WHO pre-qualification for facilities. pre-qualification for Sulphadoxine. Isoniazid plus renewals; CEP for Allopurinol & Ambroxol HCL. 2006 New plot of 1,800 SQMT; output 2017 DMF approval from UK MHRA capacity expanded to 600 MTPA. for Erythromycin Stearate. 2024 Capacity 1,800 to 2,200 MTPA; got listed on NSE. 2010 COS and EU/GMP approval for 2018 Certificate of GMP (WHO GMP) Erythromycin, Erythromycin Ethyl from FDA Maharashtra. 2025 Capacity 2,200 to 2,400 MTPA; Succinate and Pyrazinamide. CEP from EDQM for Sulfadimethoxine. 2019 WHO pre-qualification for Pyrazinamide & Sulphadoxine; EU 2026 USFDA inspection completed GMP from AEMPS Spain. successfully with zero 483 observations. 2019 New 7,800 SQMT plot (+600 MTPA); USFDA inspection passed, zero 2026 WHO pre-qualification for 483 observations. Amodiaquine HCL; awarded EcoVadis Bronze Medal. Competitive Advantage Market Leadership Why Customers Choose Anuh Products where Anuh holds a leading position Regulatory approvals Erythromycin salts USFDA, EU GMP, WHO-GMP, EDQM CEPs and WHO Geneva pre- qualifications across the portfolio. [Showing first 8,000 characters — download PDF for full document]